LX 1031

Drug Profile

LX 1031

Alternative Names: LX1031

Latest Information Update: 13 Feb 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lexicon Genetics
  • Developer Lexicon Pharmaceuticals
  • Class Gastrokinetics; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Serotonin modulators; Tryptophan hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 13 Jan 2014 Discontinued - Phase-II for Irritable bowel syndrome in USA (PO)
  • 01 May 2010 Pharmacodynamics data from a phase II trial in Irritable bowel syndrome presented at the Digestive Disease Week (DDW-2010)
  • 25 Nov 2009 Pharmacodynamics data from a clinical study in volunteers presented at the GASTRO 2009 (Joint Meeting) (GASTRO-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top